The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment

Hotez, 2010, “Manifesto” for advancing the control and elimination of neglected tropical diseases, PLoS Negl Trop Dis, 4, e718, 10.1371/journal.pntd.0000718 Beyrer, 2007, Neglected diseases, civil conflicts, and the right to health, Lancet, 370, 619, 10.1016/S0140-6736(07)61301-4 Molyneux, 2011, Neglected tropical diseases and the Millennium Development Goals—why the “other diseases” matter: reality versus rhetoric, Parasit Vectors, 4, 234, 10.1186/1756-3305-4-234 Trouiller, 2002, Drug development for neglected diseases: a deficient market and a public-health policy failure, Lancet, 359, 2188, 10.1016/S0140-6736(02)09096-7 Pécoul, 1999, Access to essential drugs in poor countries: a lost battle?, JAMA, 281, 361, 10.1001/jama.281.4.361 Hotez, 2009, Rescuing the bottom billion through control of neglected tropical diseases, Lancet, 373, 1570, 10.1016/S0140-6736(09)60233-6 Moran National Institutes of Health. ClinicalTrials.gov. http://www.clinicaltrials.gov (accessed Dec 31, 2011). Fenwick, 2012, The global burden of neglected tropical diseases, Public Health, 126, 233, 10.1016/j.puhe.2011.11.015 King, 2005, Reassessment of cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomaisis, Lancet, 365, 1561, 10.1016/S0140-6736(05)66457-4 Murray, 2012, Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2197, 10.1016/S0140-6736(12)61689-4 Cohen, 2010, development of and access to products for neglected diseases, PLoS One, 5, e10610, 10.1371/journal.pone.0010610 Spellberg, 2004, Trends in antimicrobial drug development: Implications for the future, Clin Infect Dis, 38, 1279, 10.1086/420937 Jabes, 2011, The antibiotic R&D pipeline: an update, Curr Opin Microbiol, 14, 564, 10.1016/j.mib.2011.08.002 Stefanakis, 2012, Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade, PLoS Negl Trop Dis, 6, e1803, 10.1371/journal.pntd.0001803 Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat Rev Drug Discov, 3, 711, 10.1038/nrd1470 Nwaka, 2003, Virtual drug discovery and development for neglected diseases through public-private partnerships, Nat Rev Drug Discov, 2, 919, 10.1038/nrd1230 Serdobova, 2006, Assembling a global vaccine development pipeline for infectious diseases in the developing world, Am J Public Health, 96, 1554, 10.2105/AJPH.2005.074583 Moran Røttingen, 2013, Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?, Lancet, 10.1016/S0140-6736(13)61046-6